We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Alliance Pharma Plc (APH) Ordinary 1p

Sell:35.65p Buy:35.95p 0 Change: 0.65p (1.80%)
FTSE AIM 100:0.90%
Market closed |  Prices as at close on 23 April 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:35.65p
Buy:35.95p
Change: 0.65p (1.80%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 23 April 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:35.65p
Buy:35.95p
Change: 0.65p (1.80%)
Market closed |  Prices as at close on 23 April 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Alliance Pharma plc is a United Kingdom-based consumer healthcare company. The principal activity of the Company is to act as a holding company. The principal activity of the Company is the acquisition, marketing and distribution of consumer healthcare and pharmaceutical products. The Company's segments are strategic business units that represent different parts of the overall product portfolio, these being Consumer Healthcare brands and Prescription Medicines. Its Consumer Healthcare brands include Kelo-Cote franchise, Amberen, Nizoral, MacuShield, Aloclair, Vamousse, and other consumer healthcare brands. Its Prescription Medicines include Hydromol, Flamma Franchise, Forceval and other prescription medicines. Its products include Aloclair Plus Gel, Changmin, Fazol Cream, Hydromol Ointment, Kelo-Stretch Cream, and others. It holds the marketing rights to around 80 Consumer Healthcare brands and Prescription Medicines, which are sold around the world in more than 100 countries.

Contact details

Address:
Avonbridge House, Bath Road
CHIPPENHAM
SN15 2BB
United Kingdom
Telephone:
+44 (01249) 466966
Website:
https://www.alliancepharmaceuticals.com/

Important dates

Future events
There are no future events available.
Past events
Final results 23 April 2024 23/04/24
Final results 09 April 2024 09/04/24
Trading Announcement 29 January 2024 29/01/24
Interim results 26 September 2023 26/09/23
Interim results 19 September 2023 19/09/23
Trading Announcement 18 July 2023 18/07/23
Final dividend payment date 18 July 2023 18/07/23
Final ex-dividend date 22 June 2023 22/06/23
AGM 25 May 2023 25/05/23

General stock information

EPIC:
APH
ISIN:
GB0031030819
Market cap:
£191.84 million
Shares in issue:
540.40 million
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
FTSE AIM 100,FTSE AIM All Share

Key personnel

  • Peter Butterfield
    Chief Executive Officer, Executive Director
  • Andrew Franklin
    Chief Financial Officer, Executive Director
  • Jeyan Heper
    Chief Operating Officer, Executive Director
  • Chris Chrysanthou
    Group General Counsel, Company Secretary
  • Alex Duggan
    Chief Commercial Officer, Corporate Development Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.